We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
Takeda Pharmaceutical has signed an agreement to sell around 110 of its non-core over-the-counter (OTC) and prescription pharmaceutical products to Danish pharmaceutical firm Orifarm Group for $670m.